The prevalence and natural history of anaemia in an optimally treated heart failure population

British Journal of Cardiology

Volumn 11, Issue 5, 2004, Pages 369-375

  Ryan, Enda ^a   Devlin, Maeve ^a   Prendiville, Terence ^a   Ledwidge, Mark ^a   McDonald, Kenneth ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Co morbidity; Heart failure; Prevalence of anaemia; Severity of heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HEMOGLOBIN; LOOP DIURETIC AGENT; NITRATE; WARFARIN;

ADULT; AGED; ANEMIA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE;

EID: 5344281295     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multi-disciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1990-5.
2. Haber HL, Leavey JA, Kessler PD, Kukin ML, Gottlieb SS, Packer M. The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med 1991;324:353-8.
3. Rich MW, Shah AS, Vinson JM, Freedland KE, Kuru T, Sperry JC. Iatrogenic congestive heart failure in older adults: clinical course and prognosis. J Am Geriatr Soc 1996;44:638-43.
4. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anaemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalisations. J Am Coll Cardiol 2000;35:1737-44.
5. Wisniacki N, Aimson P, Lye M. Is anaemia a cause or consequence of heart failure in the elderly? Heart 2001;85 suppl 1):4(a).
6. Norwich TB, Fonarow GC, Hamilton MA, McClellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39 1780-6.
7. Tanner H, Moschovitis G, Kuster GM et al. The prevalence of anaemia in chronic heart failure. Int J Cardiol 2002;86:115-21.
8. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anaemia in patients with heart failure. Am J Med 2003;114:112-19.
9. Ezekowitz JA, McAlister FA, Armstrong PW. Anaemia is common in heart failure and is associated with poor outcomes. Circulation 2003;107:223-5.
10. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart 2002;87:377-8.
11. Hillege HL, Girbes ARJ, de Kam PJ et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
12. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
13. Abboud C, Lichtman MA. Structure of the marrow. In: Beuler ELM, Coller BS, Kipps TJ, eds: Williams Haematology. 5th ed. New York: McGraw Hill, 1995, pp. 25-38.
14. 1 antagonists. Eur J Heart Fail 2000;2:393-8.
15. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: Results from the National Heart Failure Project. Am Heart J 2002;143 412-17.
16. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischaemia tolerance in anaemic haemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-5.
17. MacDougall IC, Lewis NP, Saunders MJ et al. Long term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990;335:489.
18. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA. Changes in left ventricular size, wall thickness, and function in anaemic patients treated with recombinant human erythropoietin. Am Heart J 1992;124:424-7.
19. Sikole A, Polenakovic M, Spiroska V, Polenakovic B, Klinkmann H, Scigalla P. Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs 2002;26 2):98-102.
20. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anaemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomised controlled study. J Am Coll Cardiol 2001;37:1775-80.
21. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne A. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107 294-9.
22. World Health Organisation. Nutritional anaemias: Report of a WHO scientific group. Geneva, Switzerland: World Health Organisation, 1968.
23. Marenzi G, Lauri G, Guazzi M et al. Cardiac and renal dysfunction in chronic heart failure: relation to neurohumoral activation and prognosis. Am J Med Sci 2001;321:359-66.
24. Sampson MJ, Drury PL. Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight and serum creatinine. Diabetes Care 1992;15:609-12.
25. Fitzsimons EJ, Brock JH. The anaemia of chronic disease. BMJ 2001;322:811-12.
26. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood 1992; 80 1639-47.
27. Joosten E, Van Loon R, Billen J, Blanckaert N, Fabri R, Pelemans W. Serum trnsferrin receptor in the evaluation of the iron status in elderly hospitalised patients with anaemia. Am J Haematol 2002;69(1):1-6.
28. van Telligen A, Kuenen JC, de Kieviet W, van Tinteren H, Kooi ML, Vasmel WL. Iron deficiency anaemia in hospitalised patients: value of various laboratory parameters. Differentiation between IDA and ACD. Neth J Med 2001;59:270-9.
29. Ryan E, Ledwidge MT, McDonald KM. Anaemia in a heart failure disease management program: iron deficiency or anaemia of chronic disease. Eur J Heart Fail 2003;2:225(a).
30. Anker SD, Sharma R, Francis DF, Pitt B, Poole-Wilson PA, Coats AJS. Haemoglobin predicts survival in patients with chronic heart failure with a U-shaped curve: a substudy of the ELITE 2 trial. Eur Heart J 2002;23: 447(a).
31. Kalra PR, Bolger AP, Francis DP et al. Effect of anaemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003;91:888-91.
32. Spivak JL. The blood in systemic disorders. Lancet 2000;355:1707-12.
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. New Engl J Med 1990;323:236-41.
34. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction. J Am Coll Cardiol 1996;27:1201-06.
35. Kubota T, Miyagishima M, Alvarez RJ et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent onset and end-stage congestive heart failure. J Heart Lung Transplant 2000; 19:819-24.
36. Ferrari R, Bachetti T, Confortini R et al. TNF soluble receptors in patients with variable degrees of congestive heart failure. Circulation 1995;92: 1479-86.
37. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating IL-6 in severe congestive heart failure. Am J Cardiol 1997;79: 1128-31.
38. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anaemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-62.
39. Alexander M, Grumbach K, Remy L, Rowell R, Massie BM. Congestive heart failure hospitalisations and survival in California: patterns according to race/ethnicity. Am Heart J 1999;137 919-27.